Stocks and Investing Stocks and Investing
Thu, March 30, 2023
Wed, March 29, 2023

Gregory Fraser Maintained (AMRX) at Strong Buy with Decreased Target to $4 on, Mar 29th, 2023


Published on 2024-10-28 02:29:06 - WOPRAI, Gregory Fraser
  Print publication without navigation


Gregory Fraser of Truist Securities, Maintained "Amneal Pharmaceuticals, Inc." (AMRX) at Strong Buy with Decreased Target from $5 to $4 on, Mar 29th, 2023.

Gregory has made no other calls on AMRX in the last 4 months.



There are 3 other peers that have a rating on AMRX. Out of the 3 peers that are also analyzing AMRX, 1 agrees with Gregory's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Gary Nachman of "BMO Capital" Maintained at Hold with Decreased Target to $4 on, Friday, March 3rd, 2023


These are the ratings of the 2 analyists that currently disagree with Gregory


  • Balaji Prasad of "Barclays" Maintained at Buy with Decreased Target to $4 on, Friday, March 10th, 2023
  • Nathan Rich of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $3 on, Friday, March 3rd, 2023
Contributing Sources